Inspire Medical Systems, Inc., the developer of the world’s first FDA-approved fully implanted neurostimulation device for Obstructive Sleep Apnea, has secured $75.0M in new funding. The capital infusion comes as the company continues to advance its unique treatment for a challenging condition.
The Inspire system incorporates a proprietary algorithm that stimulates key airway muscles based on a patient’s unique breathing patterns. This well-established neurostimulation technology is designed to reduce OSA severity and improve quality of life for patients.
